HipCheck
Stryker Corp. • Radiology • 09/29/2023
Device Purpose
HipCheck provides real-time, intra-operative quantitative measurements like the alpha angle for FAI surgery by applying an AI-driven image processing algorithm to fluoroscopic images. The accompanying HipMap FAI Analysis tool utilizes pre-operative CT scan data to generate detailed patient-specific 3D morphological reports, aiding in comprehensive surgical planning and decision-making.
Summary
HipCheck is a software system designed to aid surgeons in femoroacetabular impingement (FAI) procedures for skeletally mature patients. It operates intra-operatively, processing static fluoroscopic X-ray images to enable the superposition of virtual measurement tools, primarily for determining the alpha angle, an indicator of femoral head cam deformity. The system includes a mobile touchscreen tablet for displaying these visualizations. A complementary component, HipMap FAI Analysis, is a pre-operative tool that processes CT scans to generate patient-specific reports. These reports provide a detailed morphological analysis of the hip, including 3D reconstructions, measurements, and visualizations that describe potential FAI, hip impingement, and stability, supporting pre-operative clinical decision-making by surgeons or radiologists. The HipCheck system employs image processing algorithms, featuring an AI/Machine Learning model for detecting the femoral head and neck from fluoroscopic images. Standalone performance testing of this AI/ML model demonstrated high accuracy, correctly detecting the presence or absence of a hip with a 97.5% lower bound confidence. It precisely located femoral landmarks, with head center coordinates accurate to within approximately ±3.3-4.8% and neck angle within ±13.6-15.4°, validated across various image quality and anatomical subgroups. The HipMap FAI Analysis component relies on segmentation of pelvic CT scans for its 3D analyses; its segmentation accuracy and reliability were evaluated by comparing segmentations from Stryker personnel using HipMap software against those from third-party personnel using established software, along with intra- and inter-rater reliability assessments. Design validation further confirmed that users could effectively utilize the HipCheck tools as intended for alpha angle measurement and visualization during simulated use.
AI Regulatory Concerns
Powered by
Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.
Keywords
Device Metadata
Relevant Clinical Questions
- Q1. How does the AI/ML model's performance in HipCheck for femoral landmark detection change across varying patient BMIs or in the presence of orthopedic implants, which might alter fluoroscopic image characteristics?; What were the specific Dice similarity coefficients or surface distance errors for the HipMap FAI Analysis segmentation when benchmarked against the reference software and what was the inter-rater variability in these metrics?; What is the reported impact of using HipCheck's intra-operative alpha angle and HipMap's pre-operative analysis on surgical times, extent of bone resection, or short-term patient-reported outcomes for FAI procedures?; How does the system account for potential C-arm distortion or calibration variations during intra-operative fluoroscopic image acquisition when calculating measurements like the alpha angle?; Could the AI/ML model in HipCheck be adapted or retrained to identify other relevant anatomical structures or pathologies in the hip joint beyond the femoral head/neck for FAI?
Risk Classification
ESL AnalysisFDA Class II via 510(k) pathway; IEC 62304 Class B (software safety classification); Authorized before §524B enforcement
Learn how Parasoft automates IEC 62304 compliance testing →Cybersecurity Evidence
Powered by SBOMator™Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.
Supply Chain BOM Evidence
Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.
Analysis:
• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.
• Evidence of ML-BOM detected in AI-generated device summary.
• This device was authorized before §524B took effect. Cybersecurity evidence requirements were less prescriptive at the time.
• Postmarket cybersecurity monitoring plan not clearly documented in AI-generated device summary.
• Not detected in AI-generated device summary: SBOM, SaaSBOM, HBOM, CBOM, VDR/VEX, OBOM. These may be present in the full FDA submission.
Preparing a similar submission?
ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.
Assess Your Readiness →Or contact ESL directly